Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT03232892
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trametinib — DRUG
    Trametinib 2mg, once daily, PO, 28-day cycles

Study Details

Phase II trial to evaluate trametinib in patients with locally advanced non-squamous, non-small cell lung cancer (NSCLC) whose tumors harbor a non-synonymous NF-1 mutation, with progressive disease on at least one prior line of therapy.

Key Dates

Start date
Feb 13, 2018
Status verified
Nov 2019
Primary completion
Sep 11, 2019
Completion
Sep 11, 2019

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Trametinib 2.0mg PO daily
    Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Up to 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94115-

Find similar trials in San Francisco, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of California, San Francisco· San Francisco, CA

Related Studies